MicroPort Scientific Corporation Announces Leadership Changes in MicroPort® Orthopedics Subsidiary and Membership Changes in CEC, IEC

MicroPort Scientific Corporation announce leadership changes in MicroPort® Orthopedics subsidiary

MicroPort Scientific Corporation (“MPSC”) is pleased to announce, after approval by the Board of Directors, effective September 8th, 2015 the appointment of Mr. Aurelio Sahagun as President of MicroPort® Orthopedics. Mr. Ted Davis, will depart the role of Chief Executive Officer on the same date, and has committed to working closely with Aurelio to ensure a smooth and seamless transition. We truly appreciate Mr. Davis’ outstanding contributions to MicroPort® Orthopedics, especially throughout the organization transition and we are most grateful for his efforts in building solid foundations for the future.

Mr. Sahagun most recently served as Chief Operations Officer (“COO”) of MicroPort® Orthopedics. He joined MicroPort® Orthopedics in January 2014 as Vice President International, following the asset purchase of the OrthoRecon Business from Wright Medical Group, Inc. (“Wright Medical”), and was subsequently promoted to his current position. Mr. Sahagun has also been a member of MicroPort® Scientific’s Intercontinental Executive Committee since its inception in early 2014.

During his service with Wright Medical, Mr. Sahagun was the Corporate Officer and the Vice President of Europe, Middle East and Africa (“EMEA”) Commercial Operations since 2011, and had previously served as Vice President of Sales for the region since 2010. He joined Wright Medical in early 2006 as Director of Finance and Operations in France, and served as both Director of Finance of EMEA and Vice President of Finance of EMEA prior to the positions above. Before Wright Medical, Mr. Sahagun worked for Medtronic where he provided senior financial support to the company’s Spine business across Europe.

Mr. Sahagun began his career in Spain, where he held several finance and business management positions in banking and distribution organizations with increased responsibilities covering Spain, Portugal and Latin-America.

Mr. Sahagun holds an MBA degree from HEC (Paris, France), a Bachelor’s degree in Economics from UAM (Autonomous University of Madrid, Spain), and has followed additional Executive Education programs at Stanford Graduate School of Business (Stanford, CA - USA) and Harvard Business School (Cambridge, MA - USA).

Please join us in congratulating Aurelio for his new appointment as the Board of Directors believe his leadership, vision and passion will help MPO to succeed in the going forward and can bring the organization to the next level.
MicroPort Scientific Corporation Announces membership changes in the Greater China Executive Committee ("CEC") and Intercontinental Executive Committee ("IEC")

Effective September 8th, 2015, the following membership changes will occur for the Greater China Executive Committee and Intercontinental Executive Committee

**Greater China Executive Committee:**
- **Bo Peng**, will continue to be the Chairperson for the CEC
- **Hongbin Sun**, will continue to be the Co-Chairperson for the CEC
- **Jason Zhang**, recently joined MPSC will be the new member of the CEC.

**CEC Members:**
Bo Peng, Hongbin Sun, Jason Zhang, Qiyi Luo, Karl Pan, Yimin Xu and Junder Chiang

**Intercontinental Executive Committee:**
- **Jonathan Chen**, currently Co-Chairperson of the IEC has been appointed as the Chairperson of the IEC
- **Aurelio Sahagun**, currently an IEC member has been appointed as the Co-Chairperson of the IEC.
- **Jason Zhang**, recently joined MPSC as COO and will be a new member of the IEC
- **Todd Smith**, currently Vice President of Finance for MicroPort® Orthopedics, will be a new member of the IEC

**IEC Members:**
Jonathan Chen, Aurelio Sahagun, Hongbin Sun, Jason Zhang, Qiyi Luo, Todd Smith, and Junder Chiang
MicroPort® Attends the Ninth Oriental Cardiology Meeting

From September 10 to September 13, the 17th National Cardiovascular Conference of Chinese Medicine Association and the ninth Oriental Cardiology Conference ("CSC&OCC2015") was held in Shanghai. Nearly 10000 experts and scholars attended. Shanghai MicroPort Medical (Group) Co ("MicroPort®") held a special satellite meeting in the conference to present the independently designed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). MicroPort® shared to the attendees the latest research results of applying Firehawk® in clinical trial, evaluated Firehawk® in Health Economics, and comprehensively displayed the uniqueness and superiority of Firehawk®.

This special satellite meeting was organized by MicroPort® and held on September 12. Professor Weiyi Fang from Shanghai Chest Hospital, Professor Zuyi Yuan from the First Affiliated Hospital of Xi'an Jiaotong University, Professor Zhanquan Li from the People's Hospital of Liaoning Province, Professor Lianglong Chen from Fujian Medical University Union Hospital and Professor Ruqiong Nie from Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University were invited as chairmen of the satellite meeting. Professor Bo Xu, the Director of Fuwai Hospital presented a report titled "the new progress of clinical trials applying Firehawk®", shows the excellent clinical trial results of Firehawk®, and spoke highly of its safety and efficacy.

Professor Xiaohua Ying from the School of Public Health, Fudan University gave the following comments: "Firehawk® has better therapeutic effect in treating patients with single coronary artery lesion in single vessel, compared to imported stents of the same price." Professor Yong Xia from the Affiliated Hospital of Xuzhou Medical College shared a real case of Firehawk® with people, showing the excellent performance of Firehawk® in clinical practice to the participants earnestly.
MicroPort* held "Firehawk-Follow-2015 clinical research program and project opening meeting" on September 11. Wei Yi Fang, professor from Shanghai Chest Hospital, as the main researcher, presented the "Firehawk-Follow-2015" project to the attendees. The purpose of the project is to verify the safety and efficacy of Firehawk* in real cases. The participating experts presented and discussed the clinical research programs of Firehawk*.

During the meeting, Professor Guosheng Fu from Sir Run Run Shaw Hospital School of Medical, Zhejiang University had an interview with "Clinic" magazine. He expressed that the unique design of the groove of Firehawk* can reduce the risk of restenosis. Professor Jian An Wang from the Second Affiliated Hospital of Zhejiang University School of Medical said that the Firehawk* can reduce the time of DAPT, and he believed that if there had been more data support in real cases, Firehawk* would have been the leap progress in the field as a domestic stent. Professor Jincheng Guo from Beijing Luhe Hospital, Capital Medical University pointed out that in accordance with the definition of the ESC guidelines for a new generation of eluting stents, Firehawk* will become the most outstanding stents product after obtaining more clinical data support.
EasyFinder™ Electrophysiology Steerable Diagnostic Catheter Gains CFDA Approval


The EasyFinder™ has a deflectable tip. There are a series of electrodes at the tip of the EasyFinder™ steerable catheter to extract the electrical signal or pass pulse stimulation energy in the chamber. This product is used in conjunction with other instruments such as multi-channel electrophysiology recorder for the record and measurement of cardiac electrical signals during electrophysiological procedures. Compared with the fixed curves which are the most commonly applied in China, EasyFinder™ steerable curve has advantages to access different anatomical locations, to improve the accuracy and effectiveness of procedures, and it also reduces the radiation exposure to the doctors and patients.

The EasyFinder™’s distal segment electrodes are embedded, which ensures the smooth transition of the catheter and the clear and stable ECG signal during prolonged procedure. At the same time, the product is integrated with the hardness gradient design, which can improve the performance. The tip of EasyFinder™ is soft to reduce the myocardial injury.

EasyFinder™ received its CE mark in December 2013. It has already been distributed in Dominica, Greece, Spain and other countries, well accepted by the physicians. Gaining the approval of the CFDA means that EasyFinder™ will officially enter the domestic market, bringing more benefits to Chinese arrhythmias patients.
MicroPort® Lifesciences Attends the Fourteenth National Endocrinology Conference of Chinese Medical Association

From August 26 to August 29, MicroPort Lifesciences (Shanghai) Co ("MicroPort® Lifesciences") attended the Fourteenth National Endocrinology Conference of Chinese Medical Association, which was held in Nanjing and sponsored by Chinese Medical Association and the Chinese Medical Association Society of Endocrinology ("CSE"). The conference is the most important annual academic activity in the field of endocrine metabolic disease and clinical research in our country, attracting about 5000 domestic and foreign people in the field of endocrine to participate.

In recent years, the incidence rate of gonadal development disorders increased, and Idiopathic Hypogonadotropic Hypogonadism ("IHH") is the most common symptom. During the conference, Professor Weiqing Wang of Shanghai Ruijin Hospital, the Vice Chairman of the Chinese Medical Association, gave a presentation with the subject of "the invention and mechanism of apply GnRH pump to IHH treatment", which gave detailed description about the current status and the latest progress about the technology of applying GnRH pulse pump to IHH treatment.

Due to the abnormal GnRH hormone synthesis, function, or secretion, which lead to different degrees of deficiency of pituitary gonadotropin (LH, FSH), IHH is one of the important reasons for the delayed puberty and infertility. The incidence rate of IHH is 1/10000 in men and 1/50000 in women. The smell sense of about 60% of IHH patients are lost or decreased, known as the Calman Syndrome. The treatment methods for IHH include sex hormone replacement therapy, and GnRH pulse therapy. The GnRH pulse infusion is in accordance with the physiological regulation mechanism of pituitary gland in hypothalamus, which is the most ideal treatment method for IHH pathogenesis.
Jointly developed by the Endocrinology Department of Shanghai Ruijin Hospital and MicroPort® Lifesciences, the new generation of Hypophyseal Hormone Infusion Pump provides more ideal GnRH pulse therapy platform for the treatment of IHH, and it won the national utility model patent. This pump can carry out infusion specifical set for individuals, and the amount of injection dose is precise. The pump's pulse is fast, powerful, highly safe, and easy to operate and carry. The study shows that patients with IHH can rapidly improve the level of LH and FSH after receiving treatment using this new generation of Hypophyseal Hormone Infusion Pump. After 108 weeks of treatment for male patients, the generate rate of the sperm can reach as high as 92.1%, and the pregnancy rate as high as 87%.

In the conference, Professor Jiufeng Mao and Professor Bingkun Huang from Beijing Union Medical College Hospital, Professor Tingting Wang from Zhengzhou University First Affiliated Hospital and other experts also gave analysis and sharing about the occurrence of patients with IHH having reversed gonadal axis function, presented the comparison of treatment effectiveness between using GnRH pulse transmission inject and using HCG/HMG combined intramuscular injection for male patients with IHH, and presented report about treatment effectiveness evaluation of using GnRH pulse pump in the treatment of IHH and clinical observation. They gave high recognition of the treatment effectiveness of MicroPort® Lifesciences GnRH pituitary hormone pump.

Professor Weiqing Wang said that GnRH pituitary hormone infusion pump’s application is beyond IHH treatment. For secondary amenorrhea, hypogonadotropic amenorrhea, non-obese polycystic ovary syndrome, central amenorrhea obese polycystic ovary syndrome, it also has certain curative effect. In order to provide more standardized treatment, Ruijin Hospital Department of Endocrinology pituitary adrenal group also developed a GnRH pulse therapy clinical consensus (Draft), to promote the diagnosis and treatment of endocrine infertility, help the development of multidisciplinary cooperation and improve the treatment methods.
MicroPort® Latin America present at the 16th Brazilian Hip Congress

MicroPort® Orthopedics attended the 16th Brazilian Hip Congress from September 2 to September 5 in the city of Fortaleza, Northeast Brazil.

This is one of the major important events in the Orthopedics and Traumatology segment. About 1,200 people attended the event which occurs bi-annually.

The congress was attended by over 20 exhibitors, including Smith & Nephew, Depuy Synthes, Stryker, Aesculap, Zimmer and others.

Participation in the Congress was a great opportunity to promote the MicroPort® brand in the Brazilian Market.
MicroPort® Orthopedics APAC Region

The 16th Annual Scientific Meeting of Asian Pacific Arthroplasty Society in New Delhi, India

From September 11 to September 13, MicroPort® Orthopedics’ booth was present at APAS congress in New Delhi, India. The Asia Pacific Arthroplasty Society (“APAS”) was born 1997 when a small group of twenty orthopedic arthroplasty surgeons from the Asia-Pacific region met on the Gold Coast of Queensland, Australia to discuss the need for a scientific body to foster and represent the academic and professional needs of the region. This year 27 invited faculty and surgeons and an additional 14 colleagues delivered over 100 papers. Approximately 300 delegates attended.

2nd International Congress for Joint Reconstruction – Southeast Asia 2015, Penang Malaysia

ICJR SEA 2015 was held in Penang, Malaysia from September 14 to September 15. The theme of the meeting was “Challenges in Arthroplasty”. 21 faculty members were present and approximately 130 delegate surgeons attended.

Kris Van Thuyne, Director Marketing OrthoRecon International, attended both meetings and presented the Medial Pivot Concept to the surgeons who visited the MPO booth. Kris provided product training to the four distributors in India. After ICJR SEA, Kris presented aMP™ concepts and clinical results to the surgeons in IPOH, Malaysia and held a product training session in Perintis Medik’s office, the MPO distributor in Malaysia.
2015 Zhejiang Provincial Orthopedics Annual Academic Conference

2015 Zhejiang Provincial Orthopedics Annual Academic Conference was held in Hangzhou from September 10 to September 12. Conference invited many orthopedic experts to participate in, with more than 1000 doctor participants. Special academic lectures and discussions were given in the conference, related to all areas of new technology and clinical practice such as joints, spine, trauma, care of bone diseases and so on.

At noon on September 11, Shanghai MicroPort Orthopedics Co ("Shanghai MicroPort® Orthopedics") held a satellite meeting, with invited a professor from Zhejiang Medical University Affiliated Second Hospital as the host. A surgeon from the People’s Hospital of Zhejiang Province was invited to present a speech, “SuperPath®” micro trauma approach of total hip arthroplasty and its idea of fast track”. The satellite meeting attracted more than 200 joint surgeons to participate in, and was a great opportunity to promote the Shanghai MicroPort® Orthopedics brand in Zhejiang province. During the satellite meeting, many doctors and agents came to Shanghai MicroPort® Orthopedics’ booth to get more information about SuperPath®."
**MicroPort® Attends the 2015 ESC**

From August 27 to September 2, the 2015 European Society of Cardiology (“2015 ESC”) was held in London, UK. The European Society of Cardiology (“ESC”) has 53000 members of heart disease specialist in Europe and the Mediterranean. The purpose of the Society is to reduce the burden caused by cardiovascular disease in Europe. The Society will accomplish this mission through a variety of scientific and educational activities, including collaborative work, clinical practice guidelines, educational programs and new initiatives, the pan-European survey in the field of specific diseases, and Europe’s largest medical conference - ESC. Staffs of Microport® attended the meeting, accompanying the experts and doctors who our company invited, and together we learned about the latest international cardiovascular cutting-edge technology.
Tianjin Bohai Blood Vessel Forum

From September 11 to September 12, “China Medical Forum - Tianjin Bohai Blood Vessel Forum” was held in Tianjin. MicroPort Endovascular (Shanghai) Co (MicroPort® Endovascular) attended the meeting. During the conference, a surgeon from Department of Vascular Surgery, Tianjin Medical University General Hospital gave the opening speech; a surgeon of Shanghai Changchui Hospital shared cases of application for the heart pulse Aegis™ Bifurcated Stent-Graft System in AAA (abdominal aortic aneurysm); a surgeon from Department of vascular surgery, General Hospital of Tianjin Medical University shared clinical report of “Minos Ultra Low Profile”. All obtained high praise from the experts in the field. The meeting showed a warm atmosphere of field study and discussion.
Academic Conference in Heilongjiang

From August 21 to August 23, the “Seventh Academic Conference of Vascular Surgery Professional Committee in Heilongjiang Medical Association”, the “First plenary session of the first committee of the Department of Vascular Surgery Physician Association, Heilongjiang Physician Association” and the “2015 Local Circuit Presentation of the Department of Vascular Surgery, the Chinese Medical Association” were held in Heilongjiang Sun Island Hotel.

Microport® Endovascular attended the meeting. The meeting invited many famous experts and scholars to attend. Experts gave presentations on dozens of professional topics in Harbin city and Daqing city, which aims to make it unified, standard, scientific for the treatment of Peripheral Vascular Disease, and to improve the treatment effect, so that the patients with vascular disease can get timely diagnosis and treatment. During the conference, MicroPort® Endovascular displayed its products of Hercules™ Low Profile Straight Stent- Graft and Delivery System, Aegis™ Bifurcated Stent-Graft and Delivery System, and products operation were demonstrated on-site.
2015 Nanjing Medical University Aortic Disease Forum

On August 29 to August 30, hosted by the Second Affiliated Hospital of Nanjing Medical University, the "2015 Nanjing Medical University Aortic Disease Forum" was held. Eastern China area sales staff of MicroPort® Endovascular attended the meeting. A large number of domestic famous experts were invited to attend. During the meeting, surgeons from Nanjing General Hospital of Nanjing Military Command and Nanjing Drum Tower Hospital, shared classic cases of applied MicroPort® Endovascular’s products “Aegis” Bifurcated Stent-Graft and Delivery System” and the upcoming “Castor Thoracic Branch Stent-Graft and Delivery System” in operations.
Investor Newsletter
Issue 09 2015

For more information, please contact:

Hongbin Sun
Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600
Email: ir@microport.com